Evidence map›Paper›PMID 40560192›Full record

ArticleArchives of toxicology2025

Application of in vitro pulmonary models for hazard screening of silica particles.

Nienke Ruijter, Hedwig Braakhuis, Alberto Katsumiti, Itziar Polanco Garriz, Marie Carriere, Ilaria Zanoni, Ana Candalija, Jessica Marshall, Jolanda Vermeulen, Flemming R Cassee and 1 more

Abstract read
In one paragraph

Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Tools of the trade: leveraging 3DFrontiers in pharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nienke RuijterNational Institute for Public Health & the Environment (RIVM), Bilthoven, The Netherlands.ORCID 0009-0002-7199-8325
Hedwig BraakhuisNational Institute for Public Health & the Environment (RIVM), Bilthoven, The Netherlands.
Alberto KatsumitiGAIKER Technology Centre, Basque Research and Technology Alliance (BRTA), Zamudio, Spain.
Itziar Polanco GarrizGAIKER Technology Centre, Basque Research and Technology Alliance (BRTA), Zamudio, Spain.
Marie CarriereUniv. Grenoble-Alpes, CEA, CNRS, Grenoble INP, IRIG, SyMMES, CIBEST, Grenoble, France.ORCID 0000-0001-8446-6462
Ilaria ZanoniInstitute of Science, Technology and Sustainability for Ceramics, CNR-ISSMC, National Research Council of Italy, Faenza, Italy.ORCID 0000-0001-8692-3460
Ana CandalijaLeitat Technological Centre, Barcelona, Spain.ORCID 0000-0002-5003-3789
Jessica MarshallInstitute of Occupational Medicine (IOM), Edinburgh, UK.
Jolanda VermeulenNational Institute for Public Health & the Environment (RIVM), Bilthoven, The Netherlands.
Flemming R CasseeNational Institute for Public Health & the Environment (RIVM), Bilthoven, The Netherlands. Flemming.cassee@rivm.nl.ORCID 0000-0001-9958-8630
Matthew BoylesInstitute of Occupational Medicine (IOM), Edinburgh, UK.ORCID 0000-0003-4291-4903

Funding

H2020 Industrial Leadership 862419
6 · The paper itself

Abstract

There is an increasing need for new approach methodologies (NAMs) for safety assessment of nanomaterials (NMs) in order to keep pace with innovation. In vitro assays are useful tools during pre-market hazard screening approaches of NMs to prioritize safe(r) candidate NMs and reduce the amount of regulatory testing required. For pre-regulatory hazard screening applications, it is crucial that in vitro assays have the capacity to distinguish between NMs based on their hazard potency and have the ability to provide accurate hazard rankings. In this paper, four types of silica particles (crystalline, pyrogenic, colloidal, and silane functionalized colloidal) were subjected to twenty-four in vitro assays to obtain hazard rankings using dose-response modelling. The assays were chosen for their relevance in the mechanism of action towards pulmonary inflammation upon inhalation of silica particles. The hazard rankings of silica particles were affected by cell type (alveolar or bronchial epithelial cells, macrophages), read-out method (cell viability, release of pro-inflammatory mediators, reactive oxygen species), and exposure method (submerged, air-liquid interface), complicating the assessment of the actual human hazard. Of particular note was an often muted in vitro response to the crystalline silica used in this study (DQ12), when in vivo data ranked this material as high hazard, due to the chronic and persistent in vivo inflammatory response to crystalline silica, highlighting an important functional discord between these models. However, the potency ranking of the silica particles to induce secretion of the pro-inflammatory mediator IL-1β by THP-1 cells differentiated to M0 macrophages as well as red blood cell haemolysis corresponded more closely to the hazard ranking based on data from rat inhalation studies. These assays should be further explored as indicators for human hazard potential of silica particles and other particles following a similar mechanism of action.

Indexed as

LungSilicon DioxideToxicity TestsAnimalsCell LineCell SurvivalDose-Response Relationship, DrugEpithelial CellsHumansInhalation ExposureMacrophagesParticle SizeReactive Oxygen SpeciesRisk AssessmentReactive Oxygen SpeciesSilicon DioxideHazard screeningInhalationIn vitroNanomaterialsSilica

Identifiers

PMID40560192
PMCPMC12454472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.